Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

September 28, 2022

https://www.globenewswire.com/news-release/2022/09/28/2524125/29236/en/Cara-Therapeutics-Announces-Difelikefalin-KORSUVA-Injection-New-Drug-Application-Has-Been-Submitted-in-Japan.html

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients.

Read more at globenewswire.com

Related news for (CARA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.